Butyrate reduces high-fat diet-induced metabolic alterations, hepatic steatosis and pancreatic beta cell and intestinal barrier dysfunctions in prediabetic mice

Experimental Biology and Medicine

Volumn 242, Issue 12, 2017, Pages 1214-1226

  Matheus, V A ^a   Monteiro, L C S ^a   Oliveira, R B ^a   Maschio, D A ^a   Collares Buzato, C B ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Butyrate; high fat diet; intestinal paracellular barrier; obesity; pancreatic beta cell; type 2 diabetes mellitus

Indexed keywords

BUTYRIC ACID; CLAUDIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENTEROPATHY; FATTY LIVER; FOOD INTAKE; HISTOLOGY; HYPERGLYCEMIA; HYPERINSULINEMIA; IMMUNOBLOTTING; INSULIN RELEASE; INSULIN RESISTANCE; INTESTINE EPITHELIUM; INTESTINE MUCOSA PERMEABILITY; LIPID DIET; LIPID STORAGE; MALE; METABOLIC DISORDER; MORPHOMETRY; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET CELL HYPERPLASIA; WEIGHT GAIN; ANIMAL; C57BL MOUSE; DIETARY SUPPLEMENT; DRUG EFFECT; IMPAIRED GLUCOSE TOLERANCE; INTESTINE MUCOSA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; TIGHT JUNCTION;

ANIMALS; BUTYRIC ACID; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; FATTY LIVER; INSULIN-SECRETING CELLS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; PREDIABETIC STATE; TIGHT JUNCTIONS;

EID: 85020495969     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370217708188     Document Type: Article

References (73)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab Care 2014; 37: 81–90.
2. Thomas CC, Philipson LH. Update on diabetes classification. Med Clin North Am 2015; 99: 1–16.
3. Canivell S, Gomis R. Diagnosis and classification of autoimmune diabetes mellitus. Autoimmun Rev 2014; 13: 403–7.
4. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J 2012; 27: 269–73.
5. Tripathy D, Chavez AO. Defects in insulin secretion and action in the pathogenesis of type 2 diabetes mellitus. Curr Diab Rep 2010; 10: 184–91.
6. Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta 2014; 1842: 446–62.
7. Björnholm M, Zierath JR. Insulin signal transduction in human skeletal muscle: identifying the defects in Type II diabetes. Biochem Soc Trans 2005; 33: 354–7.
8. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev 2005; 26: 19–39.
9. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013; 93: 137–88.
10. Lin Y, Berg AH, Iyengar P, Lam TKT, Giacca A, Combs TP, Rajala MW, Du X, Rollman B, Li W, Hawkins M, Barzilai N, Rhodes CJ, Fantus IG, Brownlee M, Scherer PE. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 2005; 280: 4617–26.
11. Ghaisas S, Maher J, Kanthasamy A. Gut microbiome in health and disease: linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol Ther 2015; 158: 52–62.
12. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3: 4:279–88.
13. Amar J, Serino M, Lange C, Chabo C, Iacovoni J, Mondot S, Lepage P, Klopp C, Mariette J, Bouchez O, Perez L, Courtney M, Marre M, Klopp P, Lantieri O, Doré J, Charles M, Balkau B, Burcelin R. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia 2011; 54: 3055–61.
14. De Kort S, Keszthelyi D, Masclee AAM. Leaky gut and diabetes mellitus: what is the link? Obes Rev 2011; 12: 449–58.
15. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116: 1802–12.
16. Rhodes CJ. Type 2 diabetes - a matter of β-cell life and death? Science 2005; 307: 380–4.
17. Sone H, Kagawa Y. Pancreatic beta cell senescence contributes to the pathogenesis of type 2 diabetes in high-fat diet-induced diabetic mice. Diabetologia 2005; 48: 58–67.
18. Collares-Buzato CB. High-fat diets and β-cell dysfunction: molecular aspects. In: Mauricio D (eds) Molecular nutrition and diabetes. San Diego, USA: Elsevier, 2015, pp.115–130.
19. Oliveira RB, Maschio DA, Carvalho CPF, Collares-Buzato CB. Influence of gender and time diet exposure on endocrine pancreas remodeling in response to high fat diet-induced metabolic disturbances in mice. Ann Anat 2015; 200: 88–97.
20. Oliveira RB, Carvalho CPF, Polo CC, Dorighello GG, Boschero AC, Oliveira HCF, Collares-Buzato CB. Impaired compensatory beta-cell function and growth in response to high-fat diet in LDL receptor knockout mice. Int J Exp Pathol 2014; 95: 296–308.
21. Gómez-Dumm LA, Semino MC, Gagliardino JJ. Sequential morphological changes in pancreatic islets of spontaneously diabetic rats. Pancreas 1990; 5: 533–9.
22. Cani PD, Bibiloni R, Knauf C, Neyrinck AM, Delzenne NM. Changes in gut microbiota control metabolic diet–induced obesity and diabetes in mice. Diabetes 2008; 57: 1470–81.
23. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374–83.
24. Al-Salami H, Butt G, Fawcett JP, Tucker IG, Golocorbin-Kon S, Mikov M. Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metab Pharmacokinet 2008; 33: 101–6.
25. Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, Piemonti L, Pastore MR, Paroni R. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 2006; 49: 2824–7.
26. Neu J, Reverte CM, Mackey AD, Liboni K, Tuhacek-tenace LM, Hatch M, Li N, Caicedo RA, Schatz DA, Atkinson M. Changes in intestinal morphology and permeability in the BioBreeding rat before the onset of type 1 diabetes. J Pediatr Gatroenterol Nutr 2005; 40: 589–95.
27. Meddings JB, Jarand J, Urbanski SJ, Hardin J, Gall DG. Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. Am J Physiol 1999; 276: G951–7.
28. Matsuzaki T, Nagata Y, Kado S, Uchida K, Kato I, Hashimoto S, Yokokura T. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS 1997; 105: 643–9.
29. Wang X, He G, Peng Y, Zhong W, Wang Y, Zhang B. Sodium butyrate alleviates adipocyte inflammation by inhibiting NLRP3 pathway. Nat Sci Rep 2015; 5: 1–10.
30. Chang PV, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci 2014; 111: 2247–52.
31. Li HP, Chen X, Li MQ. Butyrate alleviates metabolic impairments and protects pancreatic beta cell function in pregnant mice with obesity. Int J Clin Exp Pathol 2013; 6: 1574–84.
32. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. The role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104–19.
33. Inan MS, Rasoulpour RJ, Yin L, Hubbard AK, Rosenberg DW, Giardina C. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterology 2000; 118: 724–34.
34. Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein claudin-1 transcription. Dig Dis Sci 2012; 57: 3126–35.
35. Khan S, Jena G. Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: a comparative study with metformin. Chem Biol Interact 2016; 254: 124–34.
36. Khan S, Jena GB. Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways: study in juvenile diabetic rat. Chem Biol Interact 2014; 213: 1–12.
37. Dudakovic A, Evans JM, Li Y, Middha S, McGee-Lawrence ME, Van Wijnen AJ, Westendorf JJ. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation. J Biol Chem 2013; 288: 28783–91.
38. Canani RB, Costanzo M Di, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011; 17: 1519–28.
39. Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, Cefalu WT, Ye J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009; 58: 1509–17.
40. Falcão VTFL, Maschio DA, de Fontes CC, Oliveira RB, Santos-Silva JC, Almeida ACS, Vanzela EC, Cartaxo MT, Carvalho CPF, Collares-Buzato CB. Reduced insulin secretion function is associated with pancreatic islet redistribution of cell adhesion molecules (CAMs) in diabetic mice after prolonged high-fat diet. Histochem Cell Biol 2016; 146: 13–31.
41. Carvalho CPF, Oliveira RB, Britan A, Santos-Silva JC, Boschero AC, Meda P, Collares-Buzato CB. Impaired β-cell-β-cell coupling mediated by Cx36 gap junctions in prediabetic mice. Am J Physiol Endocrinol Metab 2012; 303: E144–51.
42. Kim A, Miller K, Jo J, Kilimnik G, Wojcik P, Hara M. Islet architecture: a comparative study. Islets 2009; 1: 129–36.
43. Catta-Preta M, Mendonca LS, Fraulob-Aquino J, Aguila MB, Mandarim-de-Lacerda CA. A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies. Virchows Arch 2011; 459: 477–85.
44. Castro AVB, Kolka CM, Kim SP, Bergman RN, Sinai C, Angeles L. Obesity, insulin resistance and comorbidities – mechanisms of association. Arq Bras Endocrinol Metab 2015; 58: 600–9.
45. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Thierry Sulpice T, Chamontin B, Ferrières J, Tanti J-F, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761–72.
46. Johnson AMF, Costanzo A, Gareau MG, Armando AM, Quehenberger O, Jameson JM, Olefsky JM. High fat diet causes depletion of intestinal eosinophils associated with intestinal permeability. PLoS One 2015; 10: e0122195–e0122195.
47. Larsen N, Vogensen FK, Van Den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK, Abu Al-Soud W, Sørensen SJ, Hansen LH, Mogens Jakobsen M. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5: e9085–e9085.
48. Suzuki T, Hara H. Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. Nutr Metab 2010; 7: 19–19.
49. Henagan TM, Stefanska B, Fang Z, Navard AM, Ye J, Lenard NR, Devarshi PP. Sodium butyrate epigenetically modulates high-fat diet-induced skeletal muscle mitochondrial adaptation, obesity and insulin resistance through nucleosome positioning. Br J Pharmacol 2015; 172: 2782–98.
50. Yki-Järvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients 2015; 7: 9127–38.
51. Willebrords J, Veloso I, Pereira A, Maes M, Yanguas SC, Colle I, Van Den Bossche B, Da Silva TC, Oliveira CP, Andraus W, Alves VAF, Cogliati B, Vinken M. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res 2015; 59: 106–25.
52. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci 2009; 116: 539–64.
53. Dankner R, Chetrit A, Shanik MH, Raz I, Roth J. Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabs Care 2009; 32: 1464–6.
54. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 2000; 43: 1498–506.
55. Asghar Z, Yau D, Chan F, LeRoith D, Chan CB, Wheeler MB. Insulin resistance causes increased beta-cell mass but defective glucose-stimulated insulin secretion in a murine model of type 2 diabetes. Diabetologia 2006; 49: 90–9.
56. 2+ channel activities in pancreatic beta cells of non-insulin-dependent diabetes mellitus GK rats. J Clin Invest 1996; 97: 2417–25.
57. Nagaraj V, Kazim A, Helgeson J, Lewold C, Barik S, Buda P, Reinbothe TM, Wennmalm S, Zhang E, Renström E. Elevated basal insulin secretion in type 2-diabetes caused by reduced plasma membrane cholesterol. Mol Endocrinol 2016; 30: 1059–69.
58. Pinnick KE, Collins SC, Londos C, Gauguier D, Clark A, Fielding BA. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obesity 2008; 16: 522–30.
59. Valladares R, Sankar D, Li N, Williams E, Lai KK, Abdelgeliel AS, Gonzalez CF, Wasserfall CH, Larkin J, III Schatz D, Mark A, Atkinson AS, Triplett EW, Neu J, Lorca GL. Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS One 2010; 5: e10507– e10507.
60. Sapone A, De Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, Lampis R, Kryszak D, Cartenì M, Generoso M, Iafusco D, Prisco F, Laghi F, Riegler G, Carratu R, Counts D, Fasano A. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 2006; 55: 1443–9.
61. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev 2011; 91: 151–75.
62. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009; 124: 3–20.
63. Van Itallie CM, Anderson JM. Architecture of tight junctions and principles of molecular composition. Semin Cell Dev Biol 2014; 36: 157–65.
64. Krug SM, Schulzke JD, Fromm M. Tight junction, selective permeability, and related diseases. Semin Cell Dev Biol 2014; 36: 166–76.
65. Furuse M. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol 2010; 2: a002907–a002907.
66. Mukiza CN, Dubreuil DJ. Escherichia coli heat-stable toxin b impairs intestinal epithelial barrier function by altering tight junction proteins. Infect Immun 2013; 81: 2819–27.
67. Cao M, Wang P, Sun C, He W, Wang F. Amelioration of IFN-γ and TNF-α-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway. PLoS One 2013; 8: e61944–e61944.
68. Horton F, Wright J, Smith L, Hinton PJ, Robertson MD. Increased intestinal permeability to oral chromium (51Cr) -EDTA in human Type 2 diabetes. Diab Med 2014; 31: 559–63.
69. Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NMJ, Magness S, Jobin C, Lund PK. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010; 5: e12191– e12191.
70. Huang C, Song P, Fan P, Hou C, Thacker P, Ma X. Dietary Sodium butyrate decreases postweaning diarrhea by modulating intestinal permeability and changing the bacterial communities in weaned piglets. J Nutr 2015; 21: 2274–80.
71. Kumar M, Song H-J, Cho S-K, Balasubramanian S, Choe S-Y, Rho G-J. Effect of histone acetylation modification with sodium butyrate, a histone deacetylase inhibitor, on cell cycle, apoptosis, ploidy and gene expression in porcine fetal fibroblasts. J Reprod Dev 2007; 53: 903–13.
72. Luo HM, Du MH, Lin ZL, Zhang L, Ma L, Wang H, Wen Yu W, Lv Y, Lu J-Y, Pi Y-L, Hu S, Sheng Z-Y. Valproic acid treatment inhibits hypoxia-inducible factor 1α accumulation and protects against burn-induced gut barrier dysfunction in a rodent model. PLoS One 2013; 8: e77523–e77523.
73. Vinken M, De Rop E, Decrock E, De Vuyst E, Leybaert L, Vanhaecke T, Rogiers V. Epigenetic regulation of gap junctional intercellular communication: more than a way to keep cells quiet? Biochim Biophys Acta 2009; 1795: 53–61.